Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries

Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries

Summary: Background: Investing in late-stage clinical trials, trial sites, and production capacity for new health products could improve access to vaccines, therapeutics, and infectious disease diagnostics in middle-income countries. This study assesses the case for such investment in three of thes...

Full description

Bibliographic Details
Main Authors: Marco Schäferhoff, PhD, Armand Zimmerman, MS, Mohamed M Diab, MD, Wenhui Mao, PhD, Vipul Chowdhary, MD, Davinder Gill, PhD, Robert Karanja, PhD, Mziwandile Madikizela, PhD, Osondu Ogbuoji, ScD, Gavin Yamey, ProfMD
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:The Lancet Global Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2214109X22002066

Internet

http://www.sciencedirect.com/science/article/pii/S2214109X22002066

Similar Items